Total Funding
33
67
Total FundingVenture - Series Unknown raised
Growth Score
-6 pts
Heat Score
-11 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
84930
Kures is a pre-clinical-stage biopharmaceutical startup that develops opioid-based treatments for depressive disorder.
- Andrew Kruegel: President, Chief Scientific Officer & Founder
About the Company
Kures is a pre-clinical-stage biopharmaceutical startup that develops opioid-based treatments for depressive disorder.
The biopharmaceutical company is also interested in addressing other challenging indications in the psychiatry and physical pain arena using its portfolio of novel small molecules. It is currently operating in Stealth mode.
Andrew Kruegel established the biotech company in 2017 in Dobbs Ferry, New York.
